Jade Biosciences
Jade Biosciences is pioneering therapies for autoimmune diseases, focusing on developing innovative biologic delivery systems such as prefilled syringes and autoinjectors. They are advancing a pipeline of products including JADE101, which targets kidney disease, along with other candidates in preclinical stages.
Jade Biosciences is a clinical-stage biotechnology company on a mission to transform the standard of care for patients with autoimmune diseases. The company develops a pipeline of potentially best-in-class therapies built on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Its lead candidate, JADE101, is designed to inhibit the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).
Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell
11 hours ago
Guggenheim raises Jade Biosciences stock price target on pipeline progress
1 day ago
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Jade Biosciences.
Jade Biosciences Announces $135 Million Private Placement
Oct 7, 2025
Technical Lead and Subject Matter Expert for Combination Products and Drug Delivery Devices
Scholar Rock
Associate Engineering Director, Combination Drug Product/Device
Neurocrine Biosciences
Senior Engineer/Manager, Device Development — Combination Products
Oruka Therapeutics
Associate Director, Drug/Device Combination Products Tech Transfer
MSD
Sr Device Engineer I
Gilead Sciences
Engineer
Arrowhead Pharmaceuticals